ldh 3

LDH-IN-3 (compound E38) is an inhibitor of lactate dehydrogenase (LDH) and a potential protective agent against ischemic neuronal damage in the eyes and brain. It functions through the HO-1 SIRT1 pathway.

Lactate Dehydrogenase3 (LDH-3), Human Erythrocytes (LDH-3, LD3, LD-3, 2H2M), is a biological material or organic compound suitable for use in life science research.

DPP9-IN-1 (Compound 42) is an inhibitor of dipeptidyl peptidase 9 (DPP9), with an IC50 of 3 nM for DPP9 and an IC50 of 0.6 μM for DPP8. In THP-1 cells, DPP9-IN-1 induces LDH release in a concentration-dependent manner.

CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50= 34.1 nM) that reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells at a concentration of 1 μM and increases levels of 2-arachidonoyl glycerol in mouse brain at 10 mg kg.

1. Peimisine (Ebeiensine) can affect M-receptor, excit β-receptor, restrain the release of internal calcium, and promote to releaseing nitrogen monoxidum in order to relax tracheal smooth muscle and relieve asthma. 2. Peimisine can attenuate lung tissue injury( ALI), LDH and MDA amount in ALI mice in a dose dependent manner, it also lower the total protein, total white blood cells, lymphocyte and neutrophilic leukocyte in bronchoalveolar lavage fluid( BALF); suggests that peimisine can play a protective role against LPS-induced acute lung injury. 3. Peimisine has the protective effect on the experimental hepatic fibrosis formation, the possible mechanisms are associated with inhibiting fibrogenesis and fibrosis accumulation, and decreasing lipid peroxidation. 4. Peimisine can inhibit angiotensin I converting enzyme activity in a dose-dependent manner, displaying 5 % inhibitory concentration values of 526.5 microM, thus, it may have antihypertensive action.

1. 3-Dehydrotrametenolic acid can be a potential anticancer agent against H-ras transformed tumor. 2. Dehydrotrametenolic acid is a promising candidate for a new type of insulin-sensitizing drug.

N-[2-(5-Chloro-1H-indol-3-yl)ethyl]-4'-cyanobiphenyl-2-carboxaMide, a TAU cytotoxicity inhibitor, inhibits LDH leakage of M17-TAU P301L cells with EC50 of 325nM.

Antioxidant agent-3 (Compound 14q), a potent antioxidant, exhibits strong scavenging activity against DPPH radicals and ABTS+ radicals with IC50 values of 26.58 μM and 30.31 μM, respectively. Additionally, it enhances levels of reactive oxygen species (ROS), superoxide dismutase (SOD), and glutathione (GSH), while diminishing lactate dehydrogenase (LDH) in H2O2-treated HepG2 cells [1].

Zofenoprilat, an angiotensin-converting enzyme (ACE; IC50 = 8 nM for rabbit lung enzyme) inhibitor and the active metabolite of the prodrug zofenopril, effectively counters angiotensin I- or bradykinin-induced contractions in isolated guinea pig ileum (EC50s = 3 and 1 nM, respectively). At a concentration of 10 nM, Zofenoprilat not only diminishes basal endothelin-1 secretion and nitric oxide (NO) production but also safeguards against TNF-α-stimulated increases in reactive oxygen species (ROS) and reductions in glutathione (GSH) levels within human umbilical vein endothelial cells (HUVECs). Furthermore, at 10 µM, it delivers protection to primary human cardiac microvascular endothelial cells from doxorubicin-induced toxicity and enhances hydrogen sulfide (H2S) production, along with the adhesion, migration, and proliferation of HUVECs. Additionally, Zofenoprilat (400 µM) mitigates end diastolic pressure and lactate dehydrogenase (LDH) release, demonstrating therapeutic potential in a Langendorff isolated perfused rat heart model of ischemia-reperfusion injury.

3-Acetylpyridine adenine dinucleotide (3-APAD) is an analog of nicotinamide adenine dinucleotide (NAD). In conjunction with sulfites, 3-APAD effectively inhibits lactate dehydrogenase (LDH).